Ironwood Pharmaceuticals ... (IRWD)
Company Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products.
It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.
The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis.
The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide.
The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008.
Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
| Country | United States |
| IPO Date | Feb 3, 2010 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 253 |
| CEO | Thomas A. McCourt |
Contact Details
Address: 100 Summer Street Boston, Massachusetts United States | |
| Website | https://www.ironwoodpharma.com |
Stock Details
| Ticker Symbol | IRWD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001446847 |
| CUSIP Number | 46333X108 |
| ISIN Number | US46333X1081 |
| Employer ID | 04-3404176 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thomas A. McCourt | Chief Executive Officer & Director |
| Greg Martini | Senior Vice President, Chief Financial Officer & Investor Relations |
| John Minardo | Senior Vice President, Chief Legal Officer & Secretary |
| Dr. Michael Shetzline M.D., Ph.D. | Chief Medical Officer, Senior Vice President and Head of Research & Drug Development |
| Dr. Rosario Lobrutto M.B.A., M.S., Ph.D. | Vice President & Global Head of Technical Operations |
| Mike Nanfito | Vice President of Sales & Sales Excellence |
| Ronald Silver | Senior Vice President, Corporate Controller & Principal Accounting Officer |
| Tammi Gaskins | Senior Vice President & Chief Commercial Officer. |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 15, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 13, 2025 | SCHEDULE 13G | Filing |
| May 12, 2025 | 10-Q | Quarterly Report |
| May 07, 2025 | 8-K | Current Report |
| May 02, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| May 02, 2025 | SCHEDULE 13G | Filing |
| Apr 30, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Filing |
| Apr 28, 2025 | DEF 14A | Filing |